ArticleOphthalmology science2026
Plasma Metabolomic Associations with Incident Rhegmatogenous Retinal Detachment in UK Biobank.
Article in Ophthalmology science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the associations of plasma metabolites with incident rhegmatogenous retinal detachment (RRD). Design: A prospective cohort study. Subjects: A total of 213 173 UK Biobank participants. Methods: Plasma metabolomics were quantified using the Nightingale Health platform based on proton nuclear magnetic resonance spectroscopy, covering 251 metabolites. Associations with incident RRD were assessed using Cox proportional hazard models and restricted cubic splines. Two-sample Mendelian randomization analyses were conducted to assess whether genetically predicted metabolite levels showed patterns consistent with the observational associations. A metabolomic risk score (MRS) was constructed based on significant metabolites to evaluate their combined effects on RRD. Principal component analysis was used to test whether the metabolite profiles improved RRD risk prediction. Main Outcome Measures: Incident RRD, defined as the first recorded diagnosis during follow-up. Results: Over a median follow-up of 11.10 years, 1111 participants developed RRD. Seventeen metabolites were significantly associated with RRD after false discovery rate correction ( Conclusions: This study identified 17 plasma metabolites associated with RRD risk, particularly omega-3 and HDL-related lipids. Although metabolomics did not improve risk prediction, these findings provide exploratory evidence of systemic metabolic patterns associated with RRD risk. Financial Disclosures: The authors have no proprietary or commercial interest in any materials discussed in this article.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.